This talk will provide an opportunity for the learner to (anonymously) test his/her knowledge in the management of people with type 2 diabetes using cases and an ARS. The cases will also be used to illustrate the pathophysiology of type 2 diabetes and provide an opportunity for developing a practical approach to treating people with type 2 diabetes, utilizing the commonest and newest medications available. The cases will also help the learners use medications safely and understand advantages and disadvantages, and common side effects of each class of medication. Finally a practical approach to the initiation and intensification of basal insulin will be covered.

In this talk, the speaker will discuss goals of treatment as it relates to microvascular complication risk reduction and reasons for using insulin in specific populations, focusing on type 2 diabetes. Additionally, learners will review currently available short- and long-acting insulins on the U.S. market and associated risks and benefits of use. Finally, the speaker will expand on the practical use of insulin (i.e., when to start, how to titrate, etc.).

During this session (part 3 of 3 from webcast series), Dr. Aguilar and Dr. Thethi review data from cardiovascular outcomes trials for SGLT2 inhibitors and use a patient case to discuss the American Diabetes Association guidelines for individualizing diabetes therapy for patients with ASCVD, heart failure and chronic kidney disease. *Please note that any data, indications and guidelines presented in this activity are current as of the original recording on 12/3/2019, and they are subject to change as new information is published.

During this session (part 2 of 3 from webcast series), Dr. Aguilar and Dr. Thethi review data from cardiovascular outcomes trials for GLP-1 RAs and DPP-4 inhibitors. Using 2 patient cases, they discuss the American Diabetes Association guidelines for individualizing diabetes therapy for patients with ASCVD, heart failure, and chronic kidney disease. *Please note that any data, indications and guidelines presented in this activity are current as of the original recording on 12/3/2019, and they are subject to change as new information is published.

This talk will cover recent clinical trials presented at the ADA in 2019 that have an impact on the management of diabetes, such as cardiovascular outcomes trials and the first oral GLP-1 RA phase 3 data. The faculty will take you through the latest guidelines from the ADA regarding the management of type 2 diabetes and describe how recent clinical trial data has been integrated in to these guidelines. After this meeting review, you will be equipped to manage type 2 diabetes based on these guidelines. Please note that any data, indications, and guidelines presented in this activity are current as of the recording/release on February 7, 2020, and they are subject to change as new information is published.

Diabetic kidney disease is expected to surpass all other diabetes-related complications in morbidity and mortality. In this session, faculty will review current data on the renoprotective properties of SGLT2 inhibitors and explain the guideline recommendations for their use in patients with type 2 diabetes and kidney disease. *Please note that any data, indications and guidelines presented in this activity are current as of the original recording on 12/4/2019, and they are subject to change as new information is published.

Individualized care is crucial to successful type 2 diabetes (T2DM) management. The emergence of newer oral therapies that not only help to improve glycemic control but also reduce cardiovascular and other risks has dramatically changed the landscape of diabetes care. Understanding when and how to intensify treatment with this expanded toolbox is challenging for clinicians. By reviewing the latest guidelines and clinical data, participants will receive practical strategies to maximize and combine oral therapies, increase adherence, and individualize care in the treatment of diabetes.

During this session (part 1 of 3 webcast videos), Dr. Tina Thethi reviews the association between type 2 diabetes and cardiovascular disease as well as provides an overview of the American Diabetes Association guidelines designed to help individualize therapy for patients with T2DM and concurrent heart failure and/or atherosclerotic cardiovascular disease. *Please note that any data, indications and guidelines presented in this activity are current as of the original recording on 12/3/2019, and they are subject to change as new information is published.